The potential use of psychedelic drugs as therapeutics for neuropsychiatric disorders has been limited by their hallucinogenic properties. To overcome this limitation, we developed and characterized tabernanthalog (TBG), a novel analogue of the indole alkaloids ibogaine and 5-methoxy-N,N-dimethyltryptamine with reduced cardiac arrhythmogenic risk and a lack of classical psychedelic drugs-induced sensory alterations. We previously demonstrated that TBG has therapeutic efficacy in a preclinical model of opioid use disorder (OUD) in rats and in a binge model of alcohol drinking in mice. Alcohol is commonly co-used in ∼35–50% of individuals with OUD, and yet, preclinical models that recapitulate this comorbidity are lacking.
Methodology:
Here we employed a polydrug model of heroin and alcohol couse to screen the therapeutic efficacy of TBG on metrics of both opioid and alcohol seeking. We first exposed rats to alcohol (or control sucrose-fade solution) in the home-cage (HC), using a two-bottle binge protocol, over a period of 1 month. Rats were then split into two groups that underwent self-administration training for either intravenous heroin or oral alcohol, so that we could assess the impact of HC alcohol exposure on the self-administration of each substance separately. Thereafter, rats began self-administering both heroin and alcohol in the same sessions. Finally, we tested the effects of TBG on break points for heroin and alcohol in a progressive ratio test, where the number of lever presses required to obtain a single reward increased exponentially.
Results and Conclusion:
TBG effectively reduced motivation for heroin and alcohol in this test, indicating its efficacy is preserved in animals with a history of heroin and alcohol polydrug use.
Get full access to this article
View all access options for this article.
References
1.
VolkowND, CollinsFS. The role of science in addressing the opioid crisis. N Engl J Med, 2017; 377(4):391–394.
2.
TetraultJM, FiellinDA. Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs, 2012; 72(2):217–228.
3.
AlperKR, LotsofHS, RobertsT. The Use of Ibogaine in the Treatment of Addictions. Praeger Publishers: Westport, CT;, 2007; 43–66 pp.
4.
YadenDB, BerghellaAP, RegierPS, et al.Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. Int J Drug Policy, 2021; 98:103380.
5.
BogenschutzMP, JohnsonMW. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry, 2016; 64:250–258.
6.
MendesFR, CostaCdS, WiltenburgVD, et al.Classic and non-classic psychedelics for substance use disorder: A review of their historic, past and current research. Addict Neurosci, 2022; 3:100025.
7.
Garcia-RomeuA, GriffithsRR, JohnsonMW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev, 2014; 7(3):157–164.
8.
BogenschutzMP, ForcehimesAA, PommyJA, et al.Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol, 2015; 29(3):289–299.
9.
GriffithsRR, JohnsonMW, CarducciMA, et al.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol, 2016; 30(12):1181–1197.
10.
HendricksPS.Awe: A putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. Int Rev Psychiatry, 2018; 30(4):331–342.
11.
CameronLP, TombariRJ, LuJ, et al.A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature, 2021; 589(7842):474–479.
KaplanAL, ConfairDN, KimK, et al.Bespoke library docking for 5-HT(2A) receptor agonists with antidepressant activity. Nature, 2022; 610(7932):582–591.
14.
HesselgraveN, TroppoliTA, WulffAB, et al.Harnessing psilocybin: Antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A, 2021; 118(17):e2022489118.
15.
CaoD, YuJ, WangH, et al.Structure-based discovery of nonhallucinogenic psychedelic analogs. Science, 2022; 375(6579):403–411.
16.
VargasMV, MeyerR, AvanesAA, et al.Psychedelics and other psychoplastogens for treating mental illness. Front Psychiatry, 2021; 12:727117.
17.
KoenigX, HilberK. The anti-addiction drug ibogaine and the heart: A delicate relation. Molecules, 2015; 20(2):2208–2228 pp.
18.
LitjensRPW, BruntTM. How toxic is ibogaine?. Clin Toxicol, 2016; 54(4):297–302.
19.
BobashevG, TebbeK, PeiperN, et al.Polydrug use among heroin users in Cleveland, OH. Drug Alcohol Depend, 2018; 192:80–87.
20.
CiceroTJ, EllisMS, KasperZA. Polysubstance use: A broader understanding of substance use during the opioid crisis. Am J Public Health, 2020; 110(2):244–250.
21.
LorvickJ, BrowneEN, LambdinBH, et al.Polydrug use patterns, risk behavior and unmet healthcare need in a community-based sample of women who use cocaine, heroin or methamphetamine. Addict Behav, 2018; 85:94–99.
22.
McCabeSE, CranfordJA, MoralesM, et al.Simultaneous and concurrent polydrug use of alcohol and prescription drugs: Prevalence, correlates, and consequences. J Stud Alcohol, 2006; 67(4):529–537.
23.
WangL, MinJE, KrebsE, et al.Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy, 2017; 49:32–40.
24.
CrummyEA, O'NealTJ, BaskinBM, et al.One Is Not Enough: Understanding and modeling polysubstance use. Front Neurosci, 2020; 14:569.
25.
RichardsonNR, RobertsDC. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods, 1996; 66(1):1–11.
26.
National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research (U.S.), National Academies Press (U.S.). Guide for the Care and Use of Laboratory Animals. National Academies Press: Washington, DC; 2011. Available from: http://grants.nih.gov/grants/olaw/Guide-for-the-Care-and-use-of-laboratory-animals.pdf [Last accessed: January 30, 2023].
27.
FrieJA, KhokharJY. An open source automated two-bottle choice test apparatus for rats. HardwareX, 2019; 5:e00061.
28.
GodynyukE, BluittMN, TooleyJR, et al.An Open-Source, automated home-cage sipper device for monitoring liquid ingestive behavior in rodents. eNeuro, 2019; 6(5):ENEURO.0292-19.2019.
29.
WoudaJA, DiergaardeL, RigaD, et al.Disruption of long-term alcohol-related memory reconsolidation: Role of beta-adrenoceptors and NMDA receptors. Front Behav Neurosci, 2010; 4:179.
30.
BeckerHC.Alcohol dependence, withdrawal, and relapse. Alcohol Res Health, 2008; 31(4):348–361.
31.
CrabbeJC, HarrisRA, KoobGF. Preclinical studies of alcohol binge drinking. Ann N Y Acad Sci, 2011; 1216:24–40.
32.
MeyerRE, DolinskyZ.Alcohol Reinforcement: Biobehavioral and Clinical Considerations. In: Neuropharmacology of Ethanol: New Approaches. (MeyerRE, LewisMJ, KoobGF. eds.) Birkhäuser Boston: Boston, MA; 1991; pp. 251–264.
33.
SchrammMJ, EverittBJ, MiltonAL. Bidirectional modulation of alcohol-associated memory reconsolidation through manipulation of adrenergic signaling. Neuropsychopharmacology, 2016; 41(4):1103–1111.
34.
PriddyBM, CarmackSA, ThomasLC, et al.Sex, strain, and estrous cycle influences on alcohol drinking in rats. Pharmacol Biochem Behav, 2017; 152:61–67.
35.
SimmsJA, SteenslandP, MedinaB, et al.Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol Clin Exp Res, 2008; 32(10):1816–1823.
36.
FreemanKB, KearnsDN, KohutSJ, et al.Strain differences in patterns of drug-intake during prolonged access to cocaine self-administration. Behav Neurosci, 2009; 123(1):156–164.
37.
HeinsbroekJA, GiannottiG, MandelMR, et al.A common limiter circuit for opioid choice and relapse identified in a rodent addiction model. Nat Commun, 2021; 12(1):4788.
38.
GiannottiG, MottarliniF, HeinsbroekJA, et al.Oxytocin and orexin systems bidirectionally regulate the ability of opioid cues to bias reward seeking. Transl Psychiatry, 2022; 12(1):432.
39.
ShalevU, HighfieldD, YapJ, et al.Stress and relapse to drug seeking in rats: studies on the generality of the effect. Psychopharmacology (Berl), 2000; 150(3):337–346.
40.
KwanAC, OlsonDE, PrellerKH, et al.The neural basis of psychedelic action. Nat Neurosci, 2022; 25(11):1407–1419.
41.
LyC, GrebAC, CameronLP, et al.Psychedelics promote structural and functional neural plasticity. Cell Rep, 2018; 23(11):3170–3182.
42.
ShaoLX, LiaoC, GreggI, et al.Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron, 2021; 109(16):2535–2544 e4.
43.
Moda-SavaRN, MurdockMH, ParekhPK, et al.Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science, 2019; 364(6436).
44.
JonesKA, SrivastavaDP, AllenJA, et al.Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci U S A, 2009; 106(46):19575–19580.
45.
JeffersonSJ, GreggI, DibbsM, et al.5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology, 2023 [Epub ahead of print].
46.
BenesFM, VincentSL. Changes in dendritic spine morphology in response to increased availability of monoamines in rat medial prefrontal cortex. Synapse, 1991; 9(3):235–237.
47.
AmpueroE, RubioFJ, FalconR, et al.Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience, 2010; 169(1):98–108.
48.
OlsonDE.The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci, 2021; 4(2):563–567.
49.
VargasMV, DunlapLE, DongC, et al.Psychedelics promote neuroplasticity through activation of intracellular 5-HT2A receptors. Science, 2023; 379(6633):700–706.
50.
de la Fuente RevengaM, ZhuB, GuevaraCA, et al.Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep, 2021; 37(3):109836.
51.
MullerCP, HombergJR. The role of serotonin in drug use and addiction. Behav Brain Res, 2015; 277:146–192.
52.
AlexanderGM, GraefJD, HammarbackJA, et al.Disruptions in serotonergic regulation of cortical glutamate release in primate insular cortex in response to chronic ethanol and nursery rearing. Neuroscience, 2012; 207:167–181.
53.
GulatiA, BhargavaHN. Cerebral cortical 5-HT1 and 5-HT2 receptors of morphine tolerant-dependent rats. Neuropharmacology, 1988; 27(12):1231–1237.
54.
MaurelS, De VryJ, De BeunR, et al.5-HT2A and 5-HT2C/5-HT1B receptors are differentially involved in alcohol preference and consummatory behavior in cAA rats. Pharmacol Biochem Behav, 1999; 62(1):89–96.
55.
MaurelS, De VryJ, SchreiberR. 5-HT receptor ligands differentially affect operant oral self-administration of ethanol in the rat. Eur J Pharmacol, 1999; 370(3):217–223.
56.
MaguireDR, LiJX, KoekW, et al.Effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and quipazine on heroin self-administration in rhesus monkeys. Psychopharmacology (Berl), 2013; 225(1):173–185.
57.
MartinDA, GyawaliU, CaluDJ. Effects of 5-HT(2A) receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats. Addict Biol, 2021; 26(3):e12926.
58.
CaoJ, LiuX, HanS, et al.Association of the HTR2A gene with alcohol and heroin abuse. Hum Genet, 2014; 133(3):357–365.
59.
JakubczykA, WrzosekM, LukaszkiewiczJ, et al.The CC genotype in HTR2A T102C polymorphism is associated with behavioral impulsivity in alcohol-dependent patients. J Psychiatr Res, 2012; 46(1):44–49.
60.
JakubczykA, KlimkiewiczA, KoperaM, et al.The CC genotype in the T102C HTR2A polymorphism predicts relapse in individuals after alcohol treatment. J Psychiatr Res, 2013; 47(4):527–533.
61.
PolesskayaOO, SokolovBP. Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res, 2002; 67(6):812–822.
62.
FelsingDE, AnastasioNC, MiszkielJM, et al.Biophysical validation of serotonin 5-HT2A and 5-HT2C receptor interaction. PLoS One, 2018; 13(8):e0203137.
63.
AnastasioNC, StutzSJ, FinkLH, et al.Serotonin (5-HT) 5-HT2A receptor (5-HT2AR):5-HT2CR imbalance in medial prefrontal cortex associates with motor impulsivity. ACS Chem Neurosci, 2015; 6(7):1248–1258.
64.
FongangB, CunninghamKA, RowickaM, et al.Coevolution of residues provides evidence of a functional heterodimer of 5-HT(2A)R and 5-HT(2C)R involving both intracellular and extracellular domains. Neuroscience, 2019; 412:48–59.
65.
PriceAE, ShollerDJ, StutzSJ, et al.Endogenous serotonin 5-HT(2A) and 5-HT(2C) receptors associate in the medial prefrontal cortex. ACS Chem Neurosci, 2019; 10(7):3241–3248.
66.
LuJ, TjiaM, MullenB, et al.An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress. Mol Psychiatry, 2021; 26(11):6237–6252.
